UBS AM’s CME Group CME Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$596M Sell
2,700,938
-97,324
-3% -$26.9M 0.11% 152
2026
Q1
$826M Buy
2,798,262
+220,213
+9% +$65.4M 0.17% 112
2025
Q4
$704M Buy
2,578,049
+4,484
+0.2% +$1.22M 0.15% 119
2025
Q3
$695M Sell
2,573,565
-575,140
-18% -$156M 0.15% 117
2025
Q2
$868M Buy
3,148,705
+420,896
+15% +$114M 0.18% 115
2025
Q1
$724M Buy
2,727,809
+290,147
+12% +$71.6M 0.19% 111
2024
Q4
$566M Buy
2,437,662
+315,813
+15% +$72.6M 0.13% 140
2024
Q3
$468M Sell
2,121,849
-114,248
-5% -$23.6M 0.12% 156
2024
Q2
$440M Buy
2,236,097
+248,306
+12% +$51.3M 0.13% 138
2024
Q1
$428M Sell
1,987,791
-5,698
-0.3% -$1.2M 0.15% 130
2023
Q4
$420M Buy
1,993,489
+106,538
+6% +$22.7M 0.17% 124
2023
Q3
$378M Buy
1,886,951
+49,578
+3% +$9.85M 0.17% 125
2023
Q2
$352M Hold
1,837,373
0.17% 126
2023
Q1
$352M Sell
1,837,373
-3,641
-0.2% -$658K 0.17% 126
2022
Q4
$310M Sell
1,841,014
-17,564
-0.9% -$3.05M 0.16% 135
2022
Q3
$329M Sell
1,858,578
-29,916
-2% -$5.91M 0.18% 113
2022
Q2
$387M Sell
1,888,494
-88,534
-4% -$18.8M 0.2% 102
2022
Q1
$470M Buy
1,977,028
+69,786
+4% +$16.4M 0.2% 97
2021
Q4
$436M Sell
1,907,242
-58,295
-3% -$12.8M 0.17% 127
2021
Q3
$380M Buy
1,965,537
+21,832
+1% +$4.42M 0.16% 141
2021
Q2
$413M Sell
1,943,705
-95,398
-5% -$20.1M 0.18% 124
2021
Q1
$416M Buy
2,039,103
+44,291
+2% +$8.72M 0.18% 112
2020
Q4
$363M Buy
1,994,812
+245,578
+14% +$41.8M 0.17% 116
2020
Q3
$293M Buy
1,749,234
+91,365
+6% +$15.4M 0.16% 123
2020
Q2
$269M Buy
1,657,869
+40,559
+3% +$7.27M 0.16% 122
2020
Q1
$280M Buy
1,617,310
+130,412
+9% +$26M 0.2% 95
2019
Q4
$298M Buy
1,486,898
+13,423
+0.9% +$2.75M 0.18% 107
2019
Q3
$311M Sell
1,473,475
-25,570
-2% -$5.34M 0.21% 94
2019
Q2
$291M Buy
1,499,045
+92,257
+7% +$17M 0.21% 92
2019
Q1
$232M Sell
1,406,788
-20,352
-1% -$3.6M 0.17% 121
2018
Q4
$268M Sell
1,427,140
-48,776
-3% -$9.01M 0.23% 93
2018
Q3
$251M Buy
1,475,916
+8,473
+0.6% +$1.43M 0.19% 110
2018
Q2
$241M Buy
1,467,443
+37,512
+3% +$6.13M 0.18% 113
2018
Q1
$231M Buy
1,429,931
+137,425
+11% +$21.9M 0.18% 119
2017
Q4
$189M Buy
1,292,506
+2,446
+0.2% +$348K 0.16% 136
2017
Q3
$175M Buy
1,290,060
+157,680
+14% +$19.9M 0.16% 135
2017
Q2
$142M Buy
1,132,380
+72,531
+7% +$8.67M 0.14% 174
2017
Q1
$126M Sell
1,059,849
-186,457
-15% -$22.4M 0.13% 178
2016
Q4
$144M Sell
1,246,306
-304,565
-20% -$33.9M 0.16% 140
2016
Q3
$162M Buy
1,550,871
+311,074
+25% +$32.5M 0.17% 130
2016
Q2
$121M Buy
1,239,797
+444,138
+56% +$42M 0.14% 172
2016
Q1
$76.4M Sell
795,659
-776
-0.1% -$70.6K 0.09% 249
2015
Q4
$72.2M Sell
796,435
-158,662
-17% -$14.9M 0.08% 265
2015
Q3
$88.6M Sell
955,097
-102,386
-10% -$9.73M 0.1% 232
2015
Q2
$98.4M Buy
1,057,483
+6,190
+0.6% +$577K 0.09% 240
2015
Q1
$99.6M Sell
1,051,293
-46,858
-4% -$4.34M 0.1% 238
2014
Q4
$97.4M Buy
1,098,151
+11,780
+1% +$998K 0.09% 247
2014
Q3
$86.9M Buy
1,086,371
+22,406
+2% +$1.69M 0.09% 256
2014
Q2
$75.5M Buy
1,063,965
+9,895
+0.9% +$696K 0.08% 286
2014
Q1
$78M Buy
1,054,070
+69,518
+7% +$5.24M 0.08% 269
2013
Q4
$77.3M Buy
984,552
+8,157
+0.8% +$639K 0.09% 254
2013
Q3
$72.1M Buy
976,395
+271
+0% +$20K 0.09% 253
2013
Q2
$74.2M Buy
+976,124
New +$64M 0.1% 238

Other funds holding CME

UBS AM's CME Position: Q2 2026 in Review

UBS AM reduced its CME Group (CME) stake by 3.5% in Q2 2026, selling an estimated $26.9M and leaving 2,700,938 shares worth $596M. The position accounts for 0.11% of the portfolio, ranked #152.

UBS AM first reported a position in CME in Q2 2013 and has held it in 53 quarters since. The position peaked at $868M in Q2 2025. 1,694 funds tracked by Wall St. Rank hold CME as of Q2 2026.

  • UBS AM held 2,700,938 shares of CME Group worth $596M as of Q2 2026.
  • UBS AM sold 97,324 CME Group shares in Q2 2026, an estimated $26.9M.
  • CME Group made up 0.11% of UBS AM's portfolio in Q2 2026, its #152 holding.
  • UBS AM first reported a position in CME Group in Q2 2013 and has held it in 53 quarters since.
  • UBS AM's CME Group position peaked at $868M in Q2 2025.
  • 1,694 funds tracked by Wall St. Rank held CME Group as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.